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ABSTRACT 
 
Lack of access to medications has been identified as a major public health issue 
by multiple international organizations including the World Health Organization (WHO), 
the United Nations (UN), and Médecins Sans Frontières (MSF). Although medication 
access problems exist in many contexts, they are most severe and prevalent in the 
developing world. Several issues contribute to reduced medication access in low to 
middle income countries, but three interrelated factors in particular work together to 
create a cycle of imbalance that sustains the problem: high cost of medications, patent 
issues, and limited research and development into diseases that disproportionately 
affect the developing world.  
To combat limited medication access in these countries, a coordinated policy 
solution is needed that addresses challenges specific to these three factors. This 
solution includes differential pricing, compulsory licenses, and incentivizing research 
and development into neglected diseases. Centralizing these processes through an 
international agency such as WHO would provide the standardization needed to ensure 
effectiveness in many countries. By addressing these issues in the developing world 
through policy development, medication access can be improved, allowing treatment of 
infectious and chronic disease, along with potential eradication of endemic, neglected 
diseases. 
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CHAPTER I 
INTRODUCTION 
 
MEDICATION ACCESS 
Medication access has been identified as a global issue affecting health and 
health costs in both developed and developing countries. However, due to many 
factors, countries in the developing world often experience further reduced access to 
essential medicines. The World Health Organization (WHO) defines essential medicines 
as “…those that satisfy the priority health care needs of the population. They are 
selected with due regard to public health relevance, evidence on efficacy and safety, 
and comparative cost-effectiveness” (WHO, 2016b, p. 1).  
Further specifying essential medicines in regard to availability and price, WHO 
continues: 
Essential medicines are intended to be available within the context of functioning 
health systems at all times in adequate amounts, in the appropriate dosage 
forms, with assured quality and adequate information, and at a price the 
individual and the community can afford. (WHO, 2016b, p. 1) 
According to WHO (2016a), “it is estimated that one-third of the developing world’s 
people are unable to receive or purchase essential medicines on a regular basis” (p. 1). 
In fact, medication access in developing countries was recognized as a specific target in 
the United Nations (UN) Millennium Development Goals (MDG), Target 8.E: “In 
cooperation with pharmaceutical companies, provide access to affordable essential 
drugs in developing countries” (UN, 2016a, p. 1). The 2015 Report summarizing 
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progress toward the goals stated that data are limited and access is widely variable, but 
that generic medications were available in only 58% of public health facilities in low and 
middle income countries (UN, 2015). Generic medications are interchangeable with 
brand-name products but are produced by other manufacturers once the innovator 
pharmaceutical company’s patent has expired (WHO, 2016c). Therefore, most generic 
medications are much cheaper than brand-name products. Since the MDG target date 
of 2015 has passed, UN has developed 17 new Sustainable Development Goals with a 
target achievement date of 2030. Medication access is again highlighted in these goals, 
under Goal 3.8: “Achieve universal health coverage, including financial risk protection, 
access to quality essential health-care services, and access to safe, effective, quality, 
and affordable essential medicines and vaccines for all” (UN, 2016b, p. 1). Developing 
countries are specifically targeted in section 3b, which includes the declaration: “support 
the research and development of vaccines and medicines for communicable and non-
communicable diseases that primarily affect developing countries, provide access to 
affordable essential medicines and vaccines…” (UN, 2016b, p. 1). The continued 
emphasis on this issue by UN highlights the importance and timeliness of this topic.  
Although many separate efforts exist to improve medication access in the 
developing world, there is a lack of unification and coordination among programs, 
leading to a disparate system with limited power and capability. To unify these efforts 
and create a strong, organized, international system for improving medication access, 
policy changes are needed. Only through coordination will the international community 
be able to ensure access to essential medicines for the global population.  
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Purpose of Paper 
This paper will examine some of the root causes of limited medication access in 
developing countries and reasons why those causes are particularly significant in that 
context. Once those factors are discussed, individual programs or policies that could 
potentially control some of the negative influences of these factors on medication 
access in low income countries will be introduced. Finally, a coordinated policy solution 
will be proposed that would centralize these programs and provide a singular approach 
to improving medication access in developing countries.  
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CHAPTER II 
Background 
 
The problem of limited medication access is a complex issue with many causes. 
However, the root cause comes from the reality that medications are key players in two 
different contexts, both health care and economic markets (Vargas-Peláez, Rover, 
Leite, Buenaventura, & Farias, 2014). Medications are often the foundation of treatment 
for all kinds of disease, whether acute, chronic, infectious, or even genetic. Conversely, 
or perhaps as a result of their universal presence, medications have become a major 
part of both national and global economies.  
The economic value of medications is determined by many factors, not least of 
which is the cost of research, development, and manufacturing by pharmaceutical 
companies. Because of their economic value, medication pricing is strongly influenced 
by profit potential, and costs are often set to maximize profit rather than ensure access 
to all who need them. Because of this, patent issues further affect the price of 
medications, as patents are extended and novel products with only slight changes are 
developed in order to keep prices up. These novel medications may or may not provide 
great therapeutic advances, but they do allow pharmaceutical companies to continue 
marketing high-value products.  
Intellectual property battles continue to affect the availability of more affordable 
generic medications in many cases around the world. In one example, the MSF Access 
campaign works to overcome patent issues in countries with thriving generic 
manufacturing industries, such as India, Brazil, and Thailand. The MSF Access 
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Campaign is a program developed by Médecins Sans Frontières (MSF) aimed at 
increasing access to medications, diagnostic tests, and vaccines in the developing 
world (MSF, 2016). Although these same issues create problems in countries with more 
wealth, generally larger portions of the population in developed countries are able to 
afford medications, therefore having increased access and more choices, which 
continues to drive up medication-related profits. In the developing world, these same 
forces work in the opposite direction, severely limiting access to safe, efficacious 
medications. According to MSF (2016), the problem in the developing world stems from 
another cause as well; not only the high cost of existing drugs, but the lack of research 
and development surrounding medications to treat diseases predominantly found in 
disadvantaged settings. Among the many precipitating factors that limit medication 
access in developing countries, the three issues of high cost, patent disputes, and 
limited research in neglected diseases may contribute most significantly to the problem.  
Cost 
According to a 2015 report from IMS Institute for Healthcare Informatics, global 
drug spending will reach $1.4 trillion by year 2020, with emerging markets accounting 
for the majority of medicine use, while developed countries account for most of drug 
spending (IMS, 2016). This figure represents a significant increase from 2015 and 
highlights both increased medication use and cost. Medication costs continue to 
increase for a number of reasons, not only because of increased use. Pharmaceutical 
companies cite research and development costs as a main driver in overall drug costs. 
Some evidence suggests that large pharmaceutical companies like Merck, Eli Lilly, and 
Roche spend between 17% to 24% of their budgets on research and development costs 
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(George, 2015). However, pressure to produce larger profits for companies and 
investors also contributes to rising prices. To produce these profits, pharmaceutical 
companies are able to increase prices due to a lack of regulation from governments and 
limited competition within the industry (Johnson, 2015).  
For a notable example of issues surrounding drug pricing, the case of Daraprim, 
a drug used to treat toxoplasmosis in Human Immunodeficiency Virus (HIV) patients, 
highlights some of the problems with drug costs. The drug, which has the generic name 
pyrimethamine and went off patent in the 1950s, is manufactured by Turing 
Pharmaceuticals. However, there are currently no Food and Drug Administration (FDA) 
approved generic products available in the United States (U.S.), so Turing essentially 
monopolizes supply of the drug (Sanneh, 2016). After acquiring the drug in 2015, Turing 
raised the price of the drug from $13.50 per pill to $750 per pill (Kodjak, 2016). Because 
no other versions of pyrimethamine are available in the U.S., Turing is able to set the 
price at what they consider to be a fair market value. Although this example comes from 
the U.S., a developed nation, it highlights the process that happens similarly with other 
drugs in the global market. In fact, many of these issues have been brought to light 
surrounding other HIV therapies in developing countries.  
Another example involves pricing of and access to anticancer medications in 
developing countries. Lopes, Souza, and Barrios (2013) reported that in 2008, 
approximately 60% of new cancer cases occurred in low to middle income countries, 
with nearly 66% to 80% of worldwide cancer deaths occurring in these countries as well. 
These figures not only represent limited access to preventative care and improved 
diagnostics, but also to decreased access to cancer treatments compared to wealthier 
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nations. Data from a survey and focus groups of medical oncologists and healthcare 
policy experts in Southeast Asia conducted at a 2011 professional meeting suggested 
that only 15% of patients in low and middle income countries in the region had access 
to an index of selected current cancer therapies, compared to 55% access in the 
wealthier nation of Singapore (Lopes et al., 2013). These figures point out the startling 
implications of an increased need for therapies treating chronic disease, such as many 
types of cancer, in developing countries, including the inability to access newer 
therapies with improved clinical outcomes simply due to the associated cost. In order to 
understand drug cost and pricing, it is important to examine patent issues and 
intellectual property rights surrounding medications.  
Patents 
Patents have historically been used to protect intellectual property rights so that 
inventors or companies can maintain monopolies over product manufacturing to recoup 
costs associated with research and development. Patent life can vary, but for drugs, 
patents and intellectual property protection generally last 20 years (Hoen & Passarelli, 
2013). This system was meant to foster innovation by rewarding the risk and financial 
input required to develop new products (Antonanzas, Rodríguez-Ibeas, & Juárez-
Castelló, 2013). For pharmaceutical development, the patent system allowed 
companies to offset massive research and development budgets by guaranteeing sole 
manufacturing rights while a drug was still on patent. However, this system has created 
several problems specific to drug manufacturing as well, including problems that 
unequally affect the developing world. The first issue surrounds whether or not patent 
protection actually encourages innovation in drug development. One way that 
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pharmaceutical companies maintain control of products beyond patent life is by creating 
product line extensions, which markets new drugs or products under the umbrella of the 
original brand name. Similarly, companies may receive patents for new drugs which are 
not altogether new formulations, but instead only slightly vary some components of the 
original drug without altering the basic generic compound. According to Antonanzas et 
al. (2013), “less that 10% of all recently approved pharmaceutical products can really be 
qualified as new drugs” (p. 617). As these examples point out, the patent system may 
actually discourage innovation by allowing companies to continue making large profits 
off of established brand names or drugs that are extremely similar but offer extended 
patent life on the original generic compound. This situation unduly affects developing 
countries by reducing availability of more affordable generic versions of drugs not only 
for the initial patent life but, in some cases beyond, as pharmaceutical companies 
attempt to keep other companies from manufacturing generic products.  
Doha Declaration of 2001 
The Doha Declaration of 2001 attempted to circumvent some patent issues in 
developing countries by clarifying parts of the 1995 World Trade Organization 
Agreement on Trade Related Aspects of Intellectual Property Rights, or TRIPS (Hoen & 
Passarelli, 2013). TRIPS supported patents of at least 20 years on drug products but 
also allowed transition periods during which generic manufacturers in some countries 
could produce generic products before delayed patents went into effect. The most 
notable example of this policy was seen in generic manufacturing of antiretrovirals 
(ARVs), which are used to treat HIV, by companies in India. The Doha Declaration 
further delayed some of the patent initiations and created a system through which 
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governments could issue compulsory licenses to third parties to allow generic drug 
manufacturing in the interest of public health. TRIPS and the Doha Declaration are two 
examples of policies that attempted to balance intellectual property rights with the ability 
to make lower cost generic medications available in developing countries. However, the 
patent system overall still limits competition for drug companies and therefore continues 
to keep drug prices high in many cases.  
Research and Development 
A second issue related to patents that specifically affects the developing world is 
the lack of research and development into diseases that largely exist in that context. 
Research and development of diseases and drugs is limited because companies are 
not likely to see high profit returns on products used almost exclusively in developing 
countries, which have more limited ability to pay for drugs and therefore financially 
support the venture. Cost and profit potential are often in direct conflict with access to 
essential medicines when it comes to diseases that mainly affect low-income countries. 
Because research and development costs are not likely to be recouped in these cases, 
pharmaceutical companies have little to no incentive to pursue treatments for diseases 
mainly limited to the developing world. Aside from the high cost of medications and the 
limited availability of more affordable generic medications due to patent laws, this 
situation creates a third “availability problem” (Parker-Lue, Santoro, & Koski, 2015). 
Unlike the other two issues, this problem is perhaps even direr because the medications 
and treatments simply do not exist. Examples of this issue can be found in a group of 
illnesses referred to as neglected tropical diseases (NTDs). According to the Centers for 
Disease Control and Prevention (CDC, 2011), NTDs kill 534,000 people every year, 
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with 100% of low income countries affected by at least 5 NTDs. CDC classified NTDs 
into two groups: tool-ready and tool-deficient. Tool-ready NTDs are the seven NTDs 
with available diagnostic, treatment, and monitoring tools, for which control programs 
are possible or ongoing. Conversely, there are 11 tool-deficient NTDs for which the 
components of a control program, often including treatment, are not available (CDC, 
2011) (Table 2.1). Some of these diseases have available treatments which are difficult 
to administer, but many of them have no medical treatment available at all. According to 
Johnston, Ford, and Taylor (2014), “The general neglect that these diseases have 
encountered by the pharmaceutical industry means that basic research findings have 
not found their way into a drug discovery pipeline” (p. 336). The lack of interest in, and 
therefore funding towards, research and development in NTDs by pharmaceutical 
companies is compounded by the fact that drug development for these diseases is 
especially challenging. Many of the NTDs are caused by parasites, which makes drug 
discovery difficult due to the complex biology of the organisms and their use of human 
vectors for growth and transmission (Johnston et al., 2014). Strides made against NTDs 
have rested largely on prevention and treatment strategies that do not involve 
medications, with the Carter Center’s Guinea Worm Eradication Program as a hallmark 
example (Carter Center, 2016). Although programs like this can achieve success in 
some cases, their decades of work might have been shortened with the availability of 
affordable, effective medications. Development of new medications would be key in 
achieving and maintaining success against NTDs, along with many other diseases that 
largely affect the developing world.  
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TABLE 2.1 
NEGLECTED TROPICAL DISEASES, TOOL-READY AND TOOL-DEFICIENT 
 
Neglected Tropical Diseases 
Tool-Ready Tool-Deficient 
Lymphatic Filariasis Buruli ulcer 
Onchocerciasis (River Blindness) Chagas disease 
Schistosomiasis  
x Schisto 
x Bilharzia 
x Snail Fever 
Cysticercosis 
Soil-transmitted Helminths 
x Ascariasis 
x Hookworm 
x Trichuriasis (Whipworm) 
Dengue Fever 
Trachoma Echinococcosis 
 Fascioliasis (Fasciola Infection) 
African Trypanosomiasis (Sleeping 
Sickness) 
Leishmaniasis 
Hansen's Disease (Leprosy) 
Rabies 
Yaws 
 
Source:  CDC (2011) 
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CHAPTER III 
POLICY CHANGE 
 
Because the challenges facing medication access in the developing world are 
multifactorial, there is not one single solution that will solve the problem. Policy 
development in each of the three areas of cost, patents, and research and development 
are needed to ensure that all global citizens have access to affordable, effective, 
essential medicines.  
 Since cost is the most obvious contributor to decreased medication access in low 
income countries, policies are needed to regulate medication costs so that 
pharmaceutical companies maintain their right to make profits, which funds further 
research and development, while developing countries can still afford to purchase and 
provide effective essential medicines to their citizens. Several cost control approaches 
exist that provide examples for developing larger scale international policies.  
 Differential Pricing 
 One approach available is differential pricing, through which pharmaceutical 
companies sell drugs at different prices in different countries based on the economic 
standing of the country (Parker-Lue et al., 2015). This system would seem to be fair on 
the surface but can present many issues, not only with determining the appropriate 
price per country but also with determining and maintaining appropriate supply within 
the county. Because drugs are an economic commodity, the issue of parallel 
importation has arisen in the past, where some countries buy drugs at a lower price and 
resell them to other countries who would be charged a higher price by the manufacturer 
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(Parker-Lue et al., 2015). To promote appropriate differential pricing and deter parallel 
importation, a potential solution is allowing representatives from countries to negotiate 
directly with manufacturers so that exact prices paid and rebates are not widely known 
(Danzon & Towse, 2003). A uniform price is seen by all purchasers, but negotiated 
rebates would alter the actual cost so that lower income countries are able to afford the 
drugs as well. To further standardize this process, rebates would need to be based on a 
set formula that ensured countries were charged fairly through negotiations. These 
formulas could be calculated for each country by an outside body such as WHO, and 
each country’s specific formula would be kept confidential. This system would allow for 
fair differential pricing by determining each country’s ability to pay while masking the 
actual price and therefore discouraging parallel importation.   
Differential pricing would apply most often to on patent, branded products, which 
would also provide a benefit in maintaining the patent system. Since rebates would 
most often be calculated on patented drugs, pharmaceutical companies would still be 
able to generate profits exclusively for their products during the time those drugs were 
on patent. However, as special cases like the HIV pandemic have shown, the patent 
system also needs to have regulated exceptions to balance intellectual property rights 
with medication access. Through the same system that standardized individual 
country’s economic drug pricing rebate formula, WHO should also be able to provide a 
finite number of compulsory licenses for branded drugs deemed to be essential in the 
developing world.  
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Compulsory Licenses 
The continued use of compulsory licenses like those given to generic 
antiretroviral manufacturers in India would help ensure that adequate supplies of 
effective drugs were available even when a sole manufacturer still held the patent. 
Limiting compulsory licenses to drugs on the WHO essential medicines list would 
balance the patent rights of pharmaceutical companies with the need to provide those 
medicines at a lower cost in the developing worlds. Standardization of the compulsory 
licensing process could also help ensure drug quality, as generic manufacturers would 
be designated and regulated, while non-licensed manufacturers would be stopped from 
producing unregistered products. This policy would require a strong, regulatory 
presence from WHO, along with provisions for enforcement. WHO has an existing 
prequalification program that already strives to ensure quality and efficacy of some 
available medications (WHO, 2016d). However, participation in this program is 
voluntary, and as of 2013, the prequalified medications list only contained 316 drugs. 
Regulating awarding of compulsory licenses through WHO would help maintain the 
patent system by offering a limited number of licenses, while also ensuring quality by 
requiring those generic manufacturers to pass through the prequalification process.  
Incentivizing Research and Development 
Unfortunately, the use of differential pricing and compulsory licenses does not 
necessarily provide any further incentive for research and development into drug 
development for diseases largely present in low to middle income countries. Therefore, 
incentivizing research and development for these diseases, with NTDs as an example, 
would be necessary. Several schemes have been used to promote innovation in 
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disease treatments that are not likely to return a large profit to pharmaceutical 
companies.  
One example is the case of orphan drugs, or drugs that are used to treat rare 
diseases. Many developed nations, including the U.S, Japan, and the European Union, 
have programs that incentivize drug companies to produce orphan drugs. These 
incentives include marketing exclusivity, regulatory fee waivers, and tax incentives 
(Parker-Lue et al., 2015). Helping guarantee marketing exclusivity could be 
accomplished through the system of WHO regulated compulsory licenses as well. 
Allowing WHO to award a limited number of compulsory licenses would ensure that the 
pharmaceutical company that developed the drug would maintain nearly exclusive 
control through the patent life aside from the few compulsory licenses awarded. This 
would also force the pharmaceutical company to market the brand drug at a price that 
did not significantly exceed those of the few generics available, thereby providing a 
cost-containment strategy as well. WHO could also negotiate with countries where 
pharmaceutical companies were headquartered in order to help provide regulatory fee 
waivers and tax incentives for the company developing the drug.  
These incentives work for orphan drugs because companies are usually able to 
market them at extremely high prices, and the diseases are often treatable but 
incurable, providing the company a continued market despite the rarity. However, since 
the goal of many of drugs developed for low income countries would be elimination of 
disease, like with NTDs, the long-term forecast would indicate an end to the need for 
large scale manufacturing, and therefore an end to profits related to that drug. 
Therefore, in addition to incentives for that single drug, pharmaceutical companies could 
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also receive incentives towards other drugs that would be used in the developed world. 
In an example of this linking of incentives, Ridley, Grabowski, and Moe (2006) proposed 
a Priority Review Voucher, which would guarantee the pharmaceutical company an 
expedited review process through FDA in exchange for attention paid to neglected 
diseases of the developing world. In essence, the company would use the voucher to 
increase its chances of bringing to market a drug that would generate large profits in the 
developed world, potentially improving population health in both markets.  
Implications and Stakeholders 
 Improving medication access in the developing world could provide a major step 
forward in achieving a higher level of health globally through increased availability of 
treatments, as well as potential eradication of some diseases. Aside from the obvious 
health benefits, a high level of access to essential medicines worldwide would represent 
a balance between the ethical and economic considerations of drugs as both a means 
to health and a commodity. As Parker-Lue et al. (2015) note, “few would argue that our 
current system – in which the poor have significantly less access than the wealthy to 
medical care, including pharmaceuticals – is ethical” (p.192). This ethical imperative 
adds another dimension to the issue of medication access that makes the implications 
two-fold and truly unique.  
Many different parties have a stake in improving medication access, not just 
agencies like WHO and UN, NGOs like MSF, or pharmaceutical companies that 
produces the branded and generic drugs. Governmental agencies, particularly 
ministries of health, who are charged with protecting health and providing care in low 
income countries, have a vested interest in promoting improved medication access. 
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Similarly, international relief organizations such as Global Fund that support these 
countries and their need for medications through charitable giving play a key role in 
advocating for and ensuring medication access. 
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CHAPTER IV 
CONCLUSIONS/RECOMMENDATIONS 
 
 Advances in health care and public health strategies have changed the 
landscape of disease treatment and management so that many diseases are now 
curable, treatable, or manageable as chronic conditions. Medication therapy is a 
cornerstone of these treatment opportunities, and many drugs now offer improved 
efficacy and safety thanks to ongoing drug development. However, many people around 
the world, particularly in developing countries, experience limited medication access 
due to a number of factors. Of those myriad factors, drug costs, patent issues, and 
limited research and development into diseases largely found in the developing world, 
rise to the top of issues that perpetuate lack of access to essential medicines. Disparate 
programs exist that target each of these issues individually, but there is little coordinated 
effort to produce a solution that would work to mitigate all three factors at once.  
Recommendations 
A policy solution managed through WHO using differential pricing, compulsory 
licenses, and linked incentives could serve as this coordinated effort and effectively 
target these three issues in a standardized manner. As a major global public health 
issue, it is the responsibility of WHO to not only name medications to the essential 
medicines list, but also provide a solution that makes these medicines accessible, 
affordable, and safe in all countries.  
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